A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy

Liver International

Volumn 33, Issue 9, 2013, Pages 1413-1419

  Shao, Yu Yun ^a,b   Liang, Po Chin ^a   Wu, Yao Ming ^a   Huang, Chun Chieh ^c   Huang, Kai Wen ^a   Cheng, Jason C ^a,b   Hsu, Chih Hung ^a,b   Hsu, Chiun ^a,b   Cheng, Ann Lii ^a,b   Lin, Zhong Zhe ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Anti angiogenic therapy; Hepatic arterial infusion of chemotherapy; Hepatocellular carcinoma; Salvage therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; BEVACIZUMAB; BILIRUBIN; BRIVANIB; CISPLATIN; CREATININE; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; HEPARIN; NINTEDANIB; OXALIPLATIN; SORAFENIB; UFT; UROKINASE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIANGIOGENIC THERAPY; ARTICLE; BACTEREMIA; BILIRUBIN BLOOD LEVEL; BONE MARROW; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CATHETER OCCLUSION; CELLULITIS; CHILD PUGH SCORE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HEPATIC ARTERY; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTRANSAMINASEMIA; LEUKOCYTE COUNT; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; NEUTROPENIA; PILOT STUDY; PORTAL VEIN THROMBOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMACH VARICES; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTI-ANGIOGENIC THERAPY; HEPATIC ARTERIAL INFUSION OF CHEMOTHERAPY; HEPATOCELLULAR CARCINOMA; SALVAGE THERAPY;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; PILOT PROJECTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAIWAN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84883817277     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12207     Document Type: Article

References (25)

1. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
3. Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116: 4590-6.
4. Shao YY, Huang CC, Liang PC, Lin ZZ. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2010; 6: 80-8.
5. Nagano H. Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology 2010; 78(Suppl. 1): 142-7.
6. Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-95.
7. Itamoto T, Nakahara H, Tashiro H, et al. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002; 80: 143-8.
8. Lai YC, Shih CY, Jeng CM, et al. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2003; 9: 2666-70.
9. Sumie S, Yamashita F, Ando E, et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am J Roentgenol 2003; 181: 1327-34.
10. Cheong JY, Lee KM, Cho SW, et al. Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res 2005; 32: 127-33.
11. Yamasaki T, Kimura T, Kurokawa F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 2005; 40: 70-8.
12. Nagai H, Kanayama M, Higami K, et al. Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol 2007; 13: 280-4.
13. Park JY, Ahn SH, Yoon YJ, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-37.
14. Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88: 1986-91.
15. Takaki-Hamabe S, Yamasaki T, Saeki I, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol Res 2009; 39: 223-30.
16. Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol 2009; 44(Suppl. 19): 119-21.
17. Huitzil-Melendez FD, Capanu M, O'reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 2010; 28: 2889-95.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
19. Poggi G, Montagna B, Melchiorre F, et al. Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. Anticancer Res 2011; 31: 3927-33.
20. Finn RS, Kang YK, Mulcahy M, et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2090-8.
21. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-8.
22. Zhu AX, Clark JW. Commentary: sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. Oncologist 2009; 14: 67-9.
23. Worns MA, Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-95.
24. Schutte K, Zimmermann L, Bornschein J, et al. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. Digestion 2011; 83: 275-82.
25. Ministry of Health, Labour and Welfare, Japan. Comparing efficacy of sorafenib versus sorafenib in combination with low-dose FP in patients with advanced HCC. Available at http://clinicaltrials.gov/ct2/show/NCT01214343. Accessed 5 August 2012.